Publications by authors named "T M Siler"
CFTR (cystic fibrosis transmembrane conductance regulator) dysfunction is associated with mucus accumulation and worsening chronic obstructive pulmonary disease (COPD) symptoms. The aim of this phase IIb dose-finding study was to compare a CFTR potentiator, icenticaftor (QBW251), with placebo in patients with COPD and chronic bronchitis. Patients with COPD on triple therapy for at least three months were randomized to six treatment arms (icenticaftor 450, 300, 150, 75, or 25 mg or placebo twice daily [b.
View Article and Find Full Text PDFArticle Synopsis
- Ensifentrine is a new medication that inhibits two enzymes linked to lung function, providing benefits such as bronchodilation and reduced inflammation for patients with chronic obstructive pulmonary disease (COPD).
- Two large trials (ENHANCE-1 and ENHANCE-2) showed that ensifentrine significantly improved lung function and reduced symptoms and exacerbation rates compared to a placebo, but results varied between the two trials.
- The studies involved nearly 1,600 patients with moderate to severe COPD, and ensifentrine was well-tolerated, with adverse events being similar to those experienced by patients on placebo.
Background: Smoking is the major risk factor for chronic obstructive pulmonary disease (COPD). In IMPACT, single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy significantly reduced moderate/severe exacerbation rates and improved lung function and health status versus FF/VI or UMEC/VI in COPD patients. This post hoc analysis investigated trial outcomes by smoking status.
View Article and Find Full Text PDFBackground: Inhaler technique errors are common in chronic obstructive pulmonary disease (COPD) treatment, potentially leading to poor disease management. Our pooled analysis approach assessed correct use and ease-of-use of a placebo ELLIPTA dry-powder inhaler (DPI) in patients with COPD.
Methods: Adults with COPD from open-label/non-blinded studies evaluating a placebo ELLIPTA DPI and reporting outcomes of correct use (based on the ELLIPTA DPI patient information leaflet [PIL]) and/or ease-of-use were included.